Shockwave Medical

Want to better understand how Shockwave’s #ForwardIVL platform works? A new @JVascSurgCIT paper cracks deep into the design of #ShockwaveJavelin. Learn how the technical details translate into clinical outcomes in heavily calcified, stenotic peripheral arteries: jvscit.org/article/S2468-… Andrew Holden, Sameh Sayfo (@Samsayfo), Michael C. Siah (@michaelcsiah), Mario Trejo, Albert Lee, Joshua J. Popp, Nick E.J. West, John D. Corl (@JDCorlMD) US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

For Healthcare Professionals Only: 🌊 We keep on making waves in Spain with Shockwave C2 Aero first cases! From Hospital de Donostia to Hospital de Valladolid, via HUCA and Hospital Germans Trias i Pujol, the first cases with Shockwave C2 Aero are now a reality. Each procedure marks another step forward in empowering physicians to confidently address complex calcified coronary lesions. This is more than a milestone: it’s a celebration of progress in interventional cardiology and the power of innovation to transform patient care. A heartfelt thank you to the Spanish physicians leading the way and making these first cases possible. The future is sounding brighter with every pulse. #ShockwaveC2Aero #FirstCase #InterventionalCardiology #ShockwaveIVL Shockwave C2 Aero is a CE marked medical device (CE2797). For professional use only. US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

CIRSE is just around the corner – and so is the Shockwave IVL Experience Center! Join us for an immersive 3-day experience featuring hands-on sessions, live demonstrations, and expert-led discussions focused on tackling severe peripheral calcification with Shockwave IVL. The Shockwave IVL Experience Center is where learning meets real-world impact. Secure your spot today and experience Shockwave IVL in action web.cvent.com/event/f7c75583…  #CIRSE #ShockwaveIVL #ExperienceCenter #Peripheral US Rx only. Safety Info: shockwavemedical.com/isi/  Product availability may vary by country.

#ShockwaveC2Aero makes our predictably safe and consistently effective MOA more deliverable and crossable in highly stenotic and tortuous calcified anatomies. And that's just the cracking edge of our innovation pipeline. We're committed to launching at least one new catheter per year through 2030 and beyond, extending safe, effective treatment to more patients. Read this new @CardiacInterv article by our CMO, Nick West, to see how Shockwave IVL is redefining the future of calcium modification through continuous data-driven innovation: citoday.com/articles/2026-…  US Rx only. Safety Info: shockwavemedical.com/isi/  Product availability may vary by country.

At #EuroPCR 2026, the EMPOWER CAD study delivered compelling 12-month results in calcified coronary disease. 🎥 Hear CMO Dr. Nick West speak with PI Dr. Nieves Gonzalo (@NievesGonzalo1) as they discuss how the findings reinforce the safety and efficacy of a #ShockwaveIVL-first strategy in high-risk, real-world female patients. The data show sustained outcomes at 1 year, including a low need for target vessel revascularization and continued improvements in quality of life, further strengthening confidence in Shockwave IVL. Shockwave remains committed to advancing evidence in underrepresented patient populations and delivering meaningful clinical outcomes. Learn more about the EMPOWER CAD study: shockwavemedical.com/clinical-evide… US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

Interventional cardiologists: don’t miss our OPCI Observational Course from August 9– 10th led by Prof Ziad Ali (@ziadalinyc) and Drs Allen Jeremias (@DrAllenJ) and Evan Shlofmitz (@ESHLOF). During this two-day program, you’ll crack into the latest in complex PCI treatment strategies — including how to integrate intravascular imaging and #ShockwaveIVL into your workflows — through live cases, didactics and interactive discussion. Register today to attend this exciting course at St. Francis Hospital & Heart Center (@StFrancis_LI): web.cvent.com/event/8e0b5f19…  US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

Shockwave Javelin cracks occlusive calcium to enable revascularization when traditional approaches fall short. This led Dr Bill Zickler (Northeast Georgia Medical Center) to use it in a recent limb salvage intervention in a patient with challenging comorbidities. A 75M patient with a history of DM, CKD, CAD and CHF was referred to Dr Zickler due to a non-healing fifth toe wound. Angiography showed a CTO of the patient’s right anterior tibial artery. Dr Zickler gained antegrade access, and while a 0.014 guidewire crossed the lesion a 1.5 mm conventional angioplasty balloon would not. He successfully advanced Shockwave Javelin up to the occlusion, then delivered 80 pulses to cross and used the 40 remaining pulses to continue modifying the tightest part of the stenosis. Following Shockwave IVL, Dr Zickler post-dilated the vessel with a conventional angioplasty balloon and placed a bioresorbable stent to optimize luminal patency and restore flow to the patient’s distal limb. At three-month follow-up, his wound healing was excellent and tibial artery flow was improved. US Rx only.​ Safety Info link in Bio. Product availability may vary by country.

What happens when you compare #ShockwaveIVL head-to-head with atherectomy in the real world? The results speak for themselves. With 1,005 patients, the ROLLING-STONE Registry is the largest prospective, multicenter study to include a head-to-head comparison of #ShockwaveIVL and atherectomy in a real-world, all-comers population. The study confirmed strong procedural success and intraprocedural safety with Shockwave IVL. It also demonstrated a favorable 30-day MACE rate and a significantly lower 1-year MACE after propensity score matching compared with atherectomy. Read the full summary: shockwavemedical.com/education/roll…  US Rx only. Safety Info: shockwavemedical.com/isi/  Product availability may vary by country.

🧈 “Delivered like a hot knife through butter.” Hear Dr. Jeff Tyler share how he treated a late-70s male patient with a history of heart failure, angina, and low EF using the new Shockwave C2 Aero catheter. In this case, Shockwave Coronary IVL was used to address a heavily calcified LAD lesion and support optimal stent delivery and expansion. US Rx only.​ Safety Info link in Bio. Product availability may vary by country.

#ShockwaveIVL’s clinical evidence is different. Our predictably safe and consistently effective MOA has been validated by nearly 25,000 published patient outcomes across more than 600 scientific publications. To date, we have supported more than 70 company-led and investigator-initiated clinical studies, with an additional 50 planned between 2025 and 2029. Each study is designed to reflect the complex scenarios physicians encounter every day and to generate the clinical evidence needed to support confident adoption of Shockwave IVL. Read this new Cardiac Interventions Today article by our CMO, Nick West, to learn what our relentless commitment to research means for the future of calcium modification: citoday.com/articles/2026-…  US Rx only. Safety Info: shockwavemedical.com/isi/?utm_sourc… Product availability may vary by country.

For International Audiences: Patients with diabetes often represent a more complex population, but REDUCER I showed that #ShockwaveReducer delivers angina relief equally for patients suffering from diabetes.​ The trial demonstrated that device implantation was safe and just as effective at improving angina symptoms and quality of life in patients with and without diabetes.​ Explore the REDUCER I Diabetes Sub-Analysis: #study-results" target="_blank" rel="nofollow noopener">shockwavemedical.com/en-eu/disease-…  de Silva, R. Results from the REDUCER-I Study. ESC 2025​ Safety Info: shockwavemedical.com/isi/?utm_sourc… ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

@JVascSurgCIT goes into the data-backed calcium cracking capabilities of #ShockwaveJavelin 💥 The authors cover the 30-day outcomes of the Forward PAD IDE studies, dive deep into the tech that makes Shockwave Javelin unique, and review three early cases. Read the article now: jvscit.org/article/S2468-… Andrew Holden, Sameh Sayfo (@Samsayfo), Michael C. Siah (@michaelcsiah), Mario Trejo, Albert Lee, Joshua J. Popp, Nick E.J. West, John D. Corl (@JDCorlMD) US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

Designed specifically for the challenges of BTK heavily calcified peripheral artery disease, #ShockwaveJavelin modifies calcium to create a small lumen which enables further therapy to restore inline flow. Learn how this device fits into BTK interventional workflows by reading two successful case reports from Charles Bailey, MD, George Adams, MD and Vanessa Adams, BS in this Vascular Specialist article: vascularspecialistonline.com/advancing-belo…  Charles Bailey and George Adams are paid consultants of Shockwave Medical. US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.

For International Audiences: The REDUCER I trial demonstrated #ShockwaveReducer's real-world impact on patients, with the following benefits at one year:​ ➡️ 66% decrease in total number of emergency department visits in the year after implantation​ ➡️ 71% ≥1 CCS improvement ​ ➡️ 26% ≥2 CCS improvement​ Learn more: #study-results" target="_blank" rel="nofollow noopener">shockwavemedical.com/en-eu/disease-… Watch the study's lead investigator, Dr Stefan Verheye, discuss the 12-month results: youtube.com/watch?v=0ejbUL… Verheye S. et al. European Heart Journal. (2024) Vol 45 (Suppl 1)​ Safety info link in Bio. CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

When no balloon or microcatheter could initially track heavily calcified BTA vessels, Dr Manolo Rubio enlisted the help of #ShockwaveJavelin. In an @EVToday article, he describes how impactful this new device has been for enabling treatment, restoring flow and promoting wound healing in patients suffering from complex CLTI disease. Read more about his experiences and dive into a DPA CTO case spotlight here: evtoday.com/articles/2026-… Featured physicians are paid consultants of Shockwave Medical. US Rx only. Safety Info: shockwavemedical.com/isi/?utm_sourc… Product availability may vary by country.

Thrilled to announce the first SKYWARD IDE enrollment! Huge congratulations to Dr @NickMouawadMD & team at McLaren Bay Region Hospital in Bay City, MI on enrolling the first patient in the clinical program to evaluate the novel Shockwave SkyRunner Carotid IVL System for the treatment of calcified carotid arteries prior to stenting.  Read the Press Release:  shockwavemedical.com/news/johnson-j… CAUTION - Investigational device. Limited by US law to investigational use.

SKYWARD is off and running! Johnson & Johnson announced today the initiation of its SKYWARD IDE clinical program evaluating the novel Shockwave SkyRunner Carotid IVL System for the treatment of calcified carotid arteries prior to stenting. This clinical program is part of Johnson & Johnson’s plan to enhance treatment options for patients with calcified carotid artery disease, which accounts for up to one-third of all strokes. Read the Press Release: shockwavemedical.com/news/johnson-j… @JNJNews @JNJMedTech @NickMouawadMD CAUTION - Investigational device. Limited by US law to investigational use.

For International Audiences: COSIRA was the first randomized sham-controlled trial studying the use of #ShockwaveReducer for refractory angina.​ This pivotal trial demonstrated that patients who received Shockwave Reducer achieved a statistically significant improvement in angina symptoms and quality of life compared to patients in the sham control group. ​ Explore the COSIRA results: #study-results" target="_blank" rel="nofollow noopener">shockwavemedical.com/en-eu/disease-…  Verheye S. et al. Coronary sinus reducer for treatment of refractory angina: the COSIRA trial. N Engl J Med. 2015;372:519-27.​ Safety Info: shockwavemedical.com/isi/ ​ CAUTION: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada.

For Healthcare Professionals Only: Dziękuję, Poland! What inspiring days of clinical exchange. Last week, our latest device made its debut at the 2nd Kashubian-Pomeranian Interventional Cardiology Workshop, bringing together a highly engaged community of interventional cardiologists. The first clinical use, led by Dr. Michał Hawranek (@HawranekMichal), lays the groundwork for the rapid adoption of next‑generation #ShockwaveIVL technologies in Poland and further progress in calcium modification. It was a pleasure to connect and exchange valuable perspectives on how this innovation can support daily practice and advance calcium modification. Together, we’re shaping what’s next in calcium treatment. For professional use only. US Rx only. Safety Info: shockwavemedical.com/isi Product availability may vary by country.

Safety is in our DNA and MOA. #ShockwaveIVL delivers shockwaves that crack hard calcium without damaging soft tissue — the product of nearly a decade spent refining extracorporeal lithotripsy principles into a purpose-built vascular solution. The combination of Shockwave's acoustic waveform and energy delivery is what makes Shockwave IVL predictable safe and consistently effective. Learn more about our proven MOA by reading our CMO Nick West’s latest article in @CardiacInterv: citoday.com/articles/2026-…  US Rx only. Safety Info: shockwavemedical.com/isi/ Product availability may vary by country.